GlassScriptPhysician profile
Amber Drahl
NPI 1316702046
$1,095.59
in general payments reported to CMS, 2019-2025
12 companies · $711 in 2025
The $711 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $385 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $308.98 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $188.22 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $185.57 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $88.38 | 2024-2025 | |
| Organon LLC | $66.54 | 2024-2025 | Jada System |
| Sumitomo Pharma America, INC. | $62.04 | 2025 | Myfembree |
| Millicent US INC | $56.94 | 2025 | Femlyv, Intrarosa |
| Vertex Pharmaceuticals Incorporated | $47.55 | 2024-2025 | |
| Exeltis, USA INC. | $28.38 | 2024-2025 | Slynd |
| Supernus Pharmaceuticals, INC. | $25.56 | 2025 | Qelbree |
| Coopersurgical, INC. | $20.72 | 2024 | Paragard T 380a |
| Conmed Corporation | $16.71 | 2025 | Airseal, Vcare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Drahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.